Polymeric nanoparticles Potent vectors for vaccine delivery targeting cancer and infectious diseases

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 2, 2014, Pages 321-332

  Bolhassani, Azam ^a   Javanzad, Shabnam ^a,b   Saleh, Tayebeh ^c   Hashemi, Mehrdad ^b   Aghasadeghi, Mohammad Reza ^a   Sadat, Seyed Mehdi ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Gene therapy; Natural polymer; Non viral vectors; Synthetic polymer; Vaccine delivery

Indexed keywords

BETA INTERFERON; CHITOSAN; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; POLYETHYLENEIMINE; POLYGLACTIN; POLYMER; TUMOR NECROSIS FACTOR ALPHA; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT; NANOPARTICLE; VACCINE;

ARTICLE; CLINICAL STUDY; CYTOKINE PRODUCTION; DNA TRANSFECTION; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE VECTOR; HUMAN; HYDROPHILICITY; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFECTION; MALIGNANT NEOPLASTIC DISEASE; NANOPHARMACEUTICS; NONHUMAN; RNA TRANSPORT; WEST NILE FEVER; IMMUNOLOGY; INFECTION CONTROL; NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; COMMUNICABLE DISEASE CONTROL; DRUG CARRIERS; HUMANS; NANOPARTICLES; NEOPLASMS; POLYMERS; VACCINES;

EID: 84896946177     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26796     Document Type: Article

References (88)

1. Tiyaboonchai W. Chitosan nanoparticles: A promising system for drug delivery. Naresuan University Journal 2003; 11:51-66
2. Termsarasab U, Cho HJ, Kim DH, Chong S, Chung SJ, Shim CK, Moon HT, Kim DD. Chitosan oligosaccharide- arachidic acid-based nanoparticles for anti-cancer drug delivery. Int J Pharm 2013; 441:373- 80; PMID:23174411; http://dx.doi.org/10.1016/j. ijpharm.2012.11.018
3. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007; 2:751- 60; PMID:18654426; http://dx.doi.org/10.1038/ nnano.2007.387 (Pubitemid 350223348)
4. Luten J, van Nostrum CF, De Smedt SC, Hennink WE. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J Control Release 2008; 126:97-110; PMID:18201788; http://dx.doi. org/10.1016/j.jconrel.2007.10.028
5. Shenoy DB, Amiji MM. An overview of condensing and noncondensing polymeric systems for gene delivery. CSH Protoc 2007.
6. Borchard G. Chitosans for gene delivery. Adv Drug Deliv Rev 2001; 52:145-50; PMID:11718938; http://dx.doi.org/10.1016/S0169-409X(01)00198-3 (Pubitemid 33079170)
7. Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol 2013; 3:13; PMID:23532930; http://dx.doi. org/10.3389/fcimb.2013.00013
8. Saroja Ch, Lakshmi PK, Bhaskaran S. Recent trends in vaccine delivery systems: A review. Int J Pharm Investig 2011; 1:64-74; PMID:23071924; http://dx.doi.org/10.4103/2230-973X.82384
9. Davis ME. Non-viral gene delivery systems. Curr Opin Biotechnol 2002; 13:128-31; PMID:11950563; http://dx.doi.org/10.1016/S0958-1669(02)00294-X (Pubitemid 34310371)
10. Hwang SJ, Davis ME. Cationic polymers for gene delivery: designs for overcoming barriers to systemic administration. Curr Opin Mol Ther 2001; 3:183-91; PMID:11338932 (Pubitemid 32390247)
11. Xu J, Ganesh S, Amiji M. Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery. Int J Pharm 2012; 427:21-34; PMID:21621597; http://dx.doi.org/10.1016/j.ijpharm.2011.05.036
12. Mulherkar R. Gene therapy for cancer: Is there light at the end of the tunnel? J Indian Inst Sci 2012; 92:1-6
13. Mitra A, Dey B. Chitosan microspheres in novel drug delivery systems. Indian J Pharm Sci 2011; 73:355- 66; PMID:22707817
14. Jamieson GJ, Langer RS. Enhanced polymeric nanoparticles for gene delivery. Massachusetts Institute of Technology 2007, http://hdl.handle.net
15. Read ML, Logan A, Seymour LW. Barriers to gene delivery using synthetic vectors. Adv Genet 2005; 53:19-46; PMID:16240989; http://dx.doi. org/10.1016/S0065-2660(05)53002-5 (Pubitemid 43580681)
16. Liu C, Zhu Q, Wu W, Xu X, Wang X, Gao S, Liu K. Degradable copolymer based on amphiphilic N-octyl-N-quatenary chitosan and low-molecular weight polyethylenimine for gene delivery. Int J Nanomedicine 2012; 7:5339-50; PMID:23071395
17. Escriou V, Carrière M, Scherman D, Wils P. NLS bioconjugates for targeting therapeutic genes to the nucleus. Adv Drug Deliv Rev 2003; 55:295- 306; PMID:12564982; http://dx.doi.org/10.1016/ S0169-409X(02)00184-9 (Pubitemid 36135920)
18. Hébert E. Improvement of exogenous DNA nuclear importation by nuclear localization signal-bearing vectors: a promising way for non-viral gene therapy? Biol Cell 2003; 95:59-68; PMID:12799061; http://dx.doi.org/10.1016/ S0248-4900(03)00007-8 (Pubitemid 36758459)
19. Lechardeur D, Lukacs GL. Intracellular barriers to non-viral gene transfer. Curr Gene Ther 2002; 2:183-94; PMID:12109215; http://dx.doi. org/10.2174/1566523024605609
20. Sun X, Zhang N. Cationic polymer optimization for efficient gene delivery. Mini Rev Med Chem 2010; 10:108-25; PMID:20408796; http://dx.doi. org/10.2174/138955710791185109
21. Saengkrit N, Sanitrum P, Woramongkolchai N, Saesoo S, Pimpha N, Chaleawlert-Umpon S, Tencomnao T, Puttipipatkhachorn S. The PEIintroduced CS shell/PMMA core nanoparticle for silencing the expression of E6/E7 oncogenes in human cervical cells. Carbohydr Polym 2012; 90:1323- 9; PMID:22939347; http://dx.doi.org/10.1016/j. carbpol.2012.06.079
22. Huang H, Yu H, Tang G, Wang Q, Li J. Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector. Biomaterials 2010; 31:1830-8; PMID:19942284; http://dx.doi.org/10.1016/j.biomaterials.2009.11.012
23. Ko YT, Kale A, Hartner WC, Papahadjopoulos- Sternberg B, Torchilin VP. Self-assembling micelle-like nanoparticles based on phospholipidpolyethyleneimine conjugates for systemic gene delivery. J Control Release 2009; 133:132-8; PMID:18929605; http://dx.doi.org/10.1016/j. jconrel.2008.09.079
24. Torchilin VP. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 2008; 90:604- 10; PMID:18381624; http://dx.doi.org/10.1002/ bip.20989
25. Bolhasani A, Taghikhani M, Ghasemi N, Soleimanjahi H, Rafati S. Comparison of two delivery systems efficiency by using PEI for plasmid HPV16E7 DNA transfection into COS-7 cells. Modares Journal of Medical Sciences 2008; 11:15-9
26. Alexis F, Lo SL, Wang S. Covalent attachment of low molecular weight poly (ethyleneimine) improves Tat peptide mediated gene delivery. Adv Mater 2006; 18:2174-8; http://dx.doi.org/10.1002/ adma.200502173 (Pubitemid 44325314)
27. Wang S. Tat peptide conjugates of low molecular weight PEI as effective non-viral gene delivery vectors. Mol Ther 2006; 13:S76; http://dx.doi.org/10. 1016/j. ymthe.2006.08.219
28. Zhao QQ, Hu YL, Zhou Y, Li N, Han M, Tang GP, Qiu F, Tabata Y, Gao JQ. Gene-carried hepatoma targeting complex induced high gene transfection efficiency with low toxicity and significant antitumor activity. Int J Nanomedicine 2012; 7:3191-202; PMID:22811604
29. Zhang L, Gao X, Men K, Wang B, Zhang S, Qiu J, Huang M, Gou M, Huang N, Qian Z, et al. Gene therapy for C-26 colon cancer using heparin- polyethyleneimine nanoparticle-mediated survivin T34A. Int J Nanomedicine 2011; 6:2419-27; PMID:22072877
30. Gao W, Lai JC, Leung SW. Functional enhancement of chitosan and nanoparticles in cell culture, tissue engineering, and pharmaceutical applications. Front Physiol 2012; 3:321; PMID:22934070; http://dx.doi.org/10. 3389/fphys.2012.00321
31. Shi C, Zhu Y, Ran X, Wang M, Su Y, Cheng T. Therapeutic potential of chitosan and its derivatives in regenerative medicine. J Surg Res 2006; 133:185- 92; PMID:16458923; http://dx.doi.org/10.1016/j. jss.2005.12.013
32. Kuang Y, Yuan T, Zhang Z, Li M, Yang Y. Application of ferriferous oxide modified by chitosan in gene delivery. J Drug Deliv. 2012; 2012:920764
33. Garaiova Z, Strand SP, Reitan NK, Lélu S, Størset SØ, Berg K, Malmo J, Folasire O, Bjørkøy A, Davies CdeL. Cellular uptake of DNA-chitosan nanoparticles: the role of clathrin- and caveolae-mediated pathways. Int J Biol Macromol 2012; 51:1043-51; PMID:22947453; http://dx.doi.org/10.1016/j. ijbiomac.2012.08.016
34. Islam MA, Firdous J, Choi YJ, Yun CH, Cho CS. Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review. Int J Nanomedicine 2012; 7:6077-93; PMID:23271909
35. Bonnet ME, Erbacher P, Bolcato-Bellemin AL. Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharm Res 2008; 25:2972- 82; PMID:18709489; http://dx.doi.org/10.1007/ s11095-008-9693-1
36. Wang JJ, Zeng ZW, Xiao RZ, Xie T, Zhou GL, Zhan XR, Wang SL. Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine 2011; 6:765-74; PMID:21589644
37. Muzzarelli RAA. Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Mar Drugs 2010; 8:292-312; PMID:20390107; http://dx.doi.org/10.3390/md8020292
38. Ogris M, Walker G, Blessing T, Kircheis R, Wolschek M, Wagner E. Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycolpolyethylenimine/ DNA complexes. J Control Release 2003; 91:173-81; PMID:12932649; http://dx.doi. org/10.1016/S0168-3659(03)00230-X (Pubitemid 37288888)
39. Bolhassani A, Ghasemi N, Servis C, Taghikhani M, Rafati S. The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen. Drug Deliv 2009; 16:196-204; PMID:19514980; http://dx.doi. org/10.1080/10717540902757721
40. Chen H, Li P, Yin Y, Cai X, Huang Z, Chen J, Dong L, Zhang J. The promotion of type 1 T helper cell responses to cationic polymers in vivo via toll-like receptor-4 mediated IL-12 secretion. Biomaterials 2010; 31:8172-80; PMID:20692033; http://dx.doi. org/10.1016/j.biomaterials.2010.07.056
41. Huang Z, Yang Y, Jiang Y, Shao J, Sun X, Chen J, Dong L, Zhang J. Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers. Biomaterials 2013; 34:746-55; PMID:23107297; http://dx.doi. org/10.1016/j.biomaterials.2012.09.062
42. Zaharoff DA, Hance KW, Rogers CJ, Schlom J, Greiner JW. Intratumoral immunotherapy of established solid tumors with chitosan/IL-12. J Immunother 2010; 33:697-705; PMID:20664357; http://dx.doi.org/10.1097/CJI.0b013e3181eb826d
43. Graham JB. Co-delivery of cationic polymers and adenovirus in immunotherapy of prostate cancer. Chemical and Biochemical Engineering, thesis 2010.
44. Li X, Min M, Du N, Gu Y, Hode T, Naylor M, Chen D, Nordquist RE, Chen WR. Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine. Clin Dev Immunol 2013; 2013:387023; PMID:23533454; http://dx.doi.org/10.1155/2013/387023
45. van den Berg JH, Oosterhuis K, Hennink WE, Storm G, van der Aa LJ, Engbersen JF, Haanen JB, Beijnen JH, Schumacher TN, Nuijen B. Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. J Control Release 2010; 141:234- 40; PMID:19751778; http://dx.doi.org/10.1016/j. jconrel.2009.09.005
46. Coombes AGA, Lavelle EC, Jenkins PG, Davis SS. Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Vaccine 1996; 14:1429-38; PMID:8994318; http://dx.doi.org/10.1016/S0264-410X(96)00077-1 (Pubitemid 27008258)
47. Zolnik BS, González-Fernández A, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system. Endocrinology 2010; 151:458- 65; PMID:20016026; http://dx.doi.org/10.1210/ en.2009-1082
48. Nguyen DN, Green JJ, Chan JM, Langer R, Anderson DG. Polymeric materials for gene delivery and DNA vaccination. Adv Mater 2008; 20:1-21
49. Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 2012; 11:189-209; PMID:22309668; http://dx.doi. org/10.1586/erv.11.188
50. Lü JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, Chen C. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 2009; 9:325- 41; PMID:19435455; http://dx.doi.org/10.1586/ erm.09.15
51. Nandedkar TD. Nanovaccines: recent developments in vaccination. J Biosci 2009; 34:995-1003; PMID:20093753; http://dx.doi.org/10.1007/ s12038-009-0114-3
52. Espuelas S, Irache JM, Gamazo C. Synthetic particulate antigen delivery systems for vaccination. Immunología 2005; 24:208-23 (Pubitemid 41133964)
53. Otten GR, Schaefer M, Doe B, Liu H, Srivastava I, Megede Jz, Kazzaz J, Lian Y, Singh M, Ugozzoli M, et al. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol 2005; 79:8189- 200; PMID:15956564; http://dx.doi.org/10.1128/ JVI.79.13.8189-8200.2005 (Pubitemid 40853522)
54. McKeever U, Barman S, Hao T, Chambers P, Song S, Lunsford L, Hsu YY, Roy K, Hedley ML. Protective immune responses elicited in mice by immunization with formulations of poly(lactide-coglycolide) microparticles. Vaccine 2002; 20:1524- 31; PMID:11858858; http://dx.doi.org/10.1016/ S0264-410X(01)00509-6 (Pubitemid 34169791)
55. Luby TM, Cole G, Baker L, Kornher JS, Ramstedt U, Hedley ML. Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1. Clin Immunol 2004; 112:45-53 PMID:15207781; http://dx.doi.org/10.1016/j.clim.2004.04.002 (Pubitemid 38781057)
56. Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, Magill M, Silverman M, Urban RG, Hedley ML, et al. ZYC101a for treatment of highgrade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004; 103:317-26; PMID:14754702; http://dx.doi.org/10.1097/01. AOG.0000110246.93627.17
57. Sheets EE, Urban RG, Crum CP, Hedley ML, Politch JA, Gold MA, Muderspach LI, Cole GA, Crowley- Nowick PA. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 2003; 188:916- 26; PMID:12712086; http://dx.doi.org/10.1067/ mob.2003.256 (Pubitemid 36530038)
58. Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 2002; 8:1028-37; PMID:12006515 (Pubitemid 34517636)
59. Pan CH, Nair N, Adams RJ, Zink MC, Lee EY, Polack FP, Singh M, O'Hagan DT, Griffin DE. Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticleadsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques. Clin Vaccine Immunol 2008; 15:697-706; PMID:18287579; http://dx.doi. org/10.1128/CVI.00045-08 (Pubitemid 351967049)
60. Niborski V, Li Y, Brennan F, Lane M, Torché AM, Remond M, Bonneau M, Riffault S, Stirling C, Hutchings G, et al. Efficacy of particle-based DNA delivery for vaccination of sheep against FMDV. Vaccine 2006; 24:7204-13; PMID:16949709; http://dx.doi.org/10.1016/j.vaccine.2006.06.048 (Pubitemid 46127449)
61. O'Hagan DT, Singh M, Dong C, Ugozzoli M, Berger K, Glazer E, Selby M, Wininger M, Ng P, Crawford K, et al. Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine 2004; 23:672-80; PMID:15542189; http://dx.doi. org/10.1016/j.vaccine.2004.06.037 (Pubitemid 39473198)
62. Howard KA, Li XW, Somavarapu S, Singh J, Green N, Atuah KN, Ozsoy Y, Seymour LW, Alpar HO. Formulation of a microparticle carrier for oral polyplex- based DNA vaccines. Biochim Biophys Acta 2004; 1674:149-57; PMID:15374619 (Pubitemid 40125386)
63. Zhou X, Liu B, Yu X, Zha X, Zhang X, Wang X, Jin Y, Wu Y, Chen Y, Shan Y, et al. Controlled release of PEI/DNA complexes from PLGA microspheres as a potent delivery system to enhance immune response to HIV vaccine DNA prime/MVA boost regime. Eur J Pharm Biopharm 2008; 68:589-95; PMID:17950586; http://dx.doi.org/10.1016/j. ejpb.2007.09.006 (Pubitemid 351318217)
64. Kasturi SP, Sachaphibulkij K, Roy K. Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines. Biomaterials 2005; 26:6375-85; PMID:15913771; http://dx.doi.org/10. 1016/j. biomaterials.2005.03.043 (Pubitemid 40828393)
65. Pai Kasturi S, Qin H, Thomson KS, El-Bereir S, Cha SC, Neelapu S, Kwak LW, Roy K. Prophylactic antitumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. J Control Release 2006; 113:261-70; PMID:16793161; http://dx.doi. org/10.1016/j.jconrel.2006.04.006 (Pubitemid 43977789)
66. Little SR, Lynn DM, Ge Q, Anderson DG, Puram SV, Chen J, Eisen HN, Langer R. Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc Natl Acad Sci U S A 2004; 101:9534-9; PMID:15210954; http://dx.doi. org/10.1073/pnas.0403549101 (Pubitemid 38869271)
67. Bivas-Benita M, van Meijgaarden KE, Franken KL, Junginger HE, Borchard G, Ottenhoff TH, Geluk A. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A, 0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 2004; 22:1609-15; PMID:15068842; http://dx.doi. org/10.1016/j.vaccine.2003.09.044 (Pubitemid 38447207)
68. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5:387-91; PMID:10202926; http://dx.doi.org/10.1038/7385 (Pubitemid 29180575)
69. Kumar M, Behera AK, Lockey RF, Zhang J, Bhullar G, De La Cruz CP, Chen LC, Leong KW, Huang SK, Mohapatra SS. Intranasal gene transfer by chitosan- DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther 2002; 13:1415-25; PMID:12215263; http://dx.doi.org/10. 1089/10430340260185058
70. Lisziewicz J, Trocio J, Whitman L, Varga G, Xu J, Bakare N, Erbacher P, Fox C, Woodward R, Markham P, et al. DermaVir: a novel topical vaccine for HIV/AIDS. J Invest Dermatol 2005; 124:160-9; PMID:15654970; http://dx.doi. org/10.1111/j.0022-202X.2004.23535.x (Pubitemid 40100965)
71. Roos AK. Delivery of DNA vaccines against cancer. 2006, ISBN 91-7140-895-9, Karolinska Institute, Stockholm, Sweden.
72. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007; 2:469-78; PMID:18654343; http://dx.doi.org/10.1038/nnano.2007.223 (Pubitemid 47220069)
73. des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006; 116:1-27; PMID:17050027; http://dx.doi.org/10.1016/j.jconrel.2006.08.013 (Pubitemid 44792295)
74. McCarroll J, Kavallaris M. Nanoparticle delivery of siRNA as a novel therapeutic for human disease. Australian Biochemist 2012; 43:9-20
75. Moreno-Vega AI, Gomez-Quintero T, Nunez- Anita RE, Acosta-Torres LS, Castano V. Polymeric and ceramic nanoparticles in biomedical applications. Hindawi Publishing Corporation. J Nanotechnol 2012; 2012:1-10; http://dx.doi. org/10.1155/2012/936041
76. Patel MP, Patel RR, Patel JK. Chitosan mediated targeted drug delivery system: a review. J Pharm Pharm Sci 2010; 13:536-57; PMID:21486530
77. Suri SS, Fenniri H, Singh B. Nanotechnologybased drug delivery systems. J Occup Med Toxicol 2007; 2:16; PMID:18053152; http://dx.doi. org/10.1186/1745-6673-2-16
78. Prego C, Paolicelli P, Díaz B, Vicente S, Sánchez A, González-Fernández A, Alonso MJ. Chitosan-based nanoparticles for improving immunization against hepatitis B infection. Vaccine 2010; 28:2607-14; PMID:20096389; http://dx.doi.org/10.1016/j. vaccine.2010.01.011
79. Maya S, Sarmento B, Nair A, Rejnold NS, Nair SV, Jayakumar R. Smart stimuli sensitive nanogels in cancer drug delivery and imaging: A Review. Curr Pharm Des 2013; (Forthcoming); PMID:23489200
80. Seo SH, Han HD, Noh KH, Kim TW, Son SW. Chitosan hydrogel containing GM-CSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated antitumor immunity. Clin Exp Metastasis 2006; 26:179-87; http://dx.doi.org/10.1007/s10585-008-9228-5
81. Sinha D, Biswas J, Sung B, Aggarwal BB, Bishayee A. Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr Drug Targets 2012; 13:1799-819; PMID:23140290; http://dx.doi. org/10.2174/138945012804545632
82. Masuelli L, Benvenuto M, Fantini M, Marzocchella L, Sacchetti P, Di Stefano E, Tresoldi I, Izzi V, Bernardini R, Palumbo C, et al. Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice. J Biol Regul Homeost Agents 2013; 27:105-19; PMID:23489691
83. Yang C, Su X, Liu A, Zhang L, Yu A, Xi Y, Zhai G. Advances in clinical study of curcumin. Curr Pharm Des 2013; 19:1966-73; PMID:23116307
84. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanomedicine: a road to cancer therapeutics. Curr Pharm Des 2013; 19:1994-2010; PMID:23116309
85. Zou P, Helson L, Maitra A, Stern ST, McNeil SE. Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats. Mol Pharm 2013; 10:1977-87; PMID:23534919; http://dx.doi.org/10.1021/mp4000019
86. Liu L, Sun L, Wu Q, Guo W, Li L, Chen Y, Li Y, Gong C, Qian Z, Wei Y. Curcumin loaded polymeric micelles inhibit breast tumor growth and spontaneous pulmonary metastasis. Int J Pharm 2013; 443:175- 82; PMID:23287774; http://dx.doi.org/10.1016/j. ijpharm.2012.12.032
87. Jiang M, Huang O, Zhang X, Xie Z, Shen A, Liu H, Geng M, Shen K. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen- resistant breast cancer cell lines MCF-7/ LCC2 and MCF-7/LCC9. Molecules 2013; 18:701- 20; PMID:23299550; http://dx.doi.org/10.3390/ molecules18010701
88. Parveen S, Sahoo SK. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharmacol 2011; 670:372-83; PMID:21951969; http://dx.doi.org/10.1016/j.ejphar.2011.09.023